Sign up to save your podcasts
Or
Share Nvidia vs US, Europe Moves On & China Seems Less Bad?
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Nvidia vs US, Europe Moves On & China Seems Less Bad?
AI hits a trust wall, healthcare costs spike, and Europe locks in deals with India & China instead of the US.
In this update, we discuss how leaders in artificial intelligence like Jensen Huang and Sam Altman are navigating significant industry changes. We also examine critical shifts in healthcare, including actions impacting prescription drugs and insurers. Lastly, we touch on broader geopolitics, noting Europe's evolving global strategy and China's biotech progress.
What you’ll learn
- Why Congress thinks Nvidia has been helping China’s DeepSeek AI & why we need stronger export controls
- Why the real issue is corporate incentives vs national security
- What it means if the Nvidia–OpenAI mega-partnership is truly on ice
- OpenAI’s cash runway problem and why IPO pressure changes behavior
- Why TikTok’s ownership shift still leaves the “algorithm control” question open
- Yahoo’s AI search strategy and why licensed content is a differentiator
- How Medicare’s rate stance translates into real insurer pressure and lobbying
- What 872 drug price hikes signal about pricing power and enforcement limits
- What the preservative studies suggest, and why regulators are being pressed to respond
- Why China’s biotech model is working, and what parity implies for US leadership
- How the EU–India deal and sovereign satellites fit into the new bloc era
- Why Japan’s maglev is more than a “cool train story”
Chapters
00:00 – The week’s collision: AI, healthcare, and global realignment
00:57 – Nvidia accused of aiding China’s DeepSeek: the letter and the stakes
02:47 – Nvidia–OpenAI partnership on ice, OpenAI’s funding clock, and AI talent drama
04:50 – TikTok becomes a “US company”: what changed, what did not
06:00 – Yahoo’s AI search comeback and the licensed-content model
07:14 – Medicare’s rate stance: $90B shock and why insurers will push back
10:10 – 872 drug price hikes and where pricing power ends
10:25 – Preservatives linked to cancer and diabetes risk: what the studies claim
11:46 – China’s biotech blitz and US strategic drift
13:59 – Europe rewires: EU–India deal, US–India move, and the sovereignty push
15:58 – Google cyber offensive and botnet disruption
17:07 – Germany EV credits, EU satellite comms, and the “decoupling” problem
18:45 – ECB: the WTO and China as the inflection point
20:06 – One good thing: Japan’s 603 km/h maglev
21:21 – Wrap
FOLLOW GOOD REVENUE
- YouTube: https://www.youtube.com/channel/UCHrhuWbpYnUwrR75H2Ip4yQ
- Spotify: https://open.spotify.com/show/44me6PABSQ0k0GfphM70au
- Apple Podcast: https://podcasts.apple.com/us/podcast/good-revenue/id1707461473
Hosted on Acast. See acast.com/privacy for more information.
View all episodes
By Neeta BidwaiAI hits a trust wall, healthcare costs spike, and Europe locks in deals with India & China instead of the US.
In this update, we discuss how leaders in artificial intelligence like Jensen Huang and Sam Altman are navigating significant industry changes. We also examine critical shifts in healthcare, including actions impacting prescription drugs and insurers. Lastly, we touch on broader geopolitics, noting Europe's evolving global strategy and China's biotech progress.
What you’ll learn
- Why Congress thinks Nvidia has been helping China’s DeepSeek AI & why we need stronger export controls
- Why the real issue is corporate incentives vs national security
- What it means if the Nvidia–OpenAI mega-partnership is truly on ice
- OpenAI’s cash runway problem and why IPO pressure changes behavior
- Why TikTok’s ownership shift still leaves the “algorithm control” question open
- Yahoo’s AI search strategy and why licensed content is a differentiator
- How Medicare’s rate stance translates into real insurer pressure and lobbying
- What 872 drug price hikes signal about pricing power and enforcement limits
- What the preservative studies suggest, and why regulators are being pressed to respond
- Why China’s biotech model is working, and what parity implies for US leadership
- How the EU–India deal and sovereign satellites fit into the new bloc era
- Why Japan’s maglev is more than a “cool train story”
Chapters
00:00 – The week’s collision: AI, healthcare, and global realignment
00:57 – Nvidia accused of aiding China’s DeepSeek: the letter and the stakes
02:47 – Nvidia–OpenAI partnership on ice, OpenAI’s funding clock, and AI talent drama
04:50 – TikTok becomes a “US company”: what changed, what did not
06:00 – Yahoo’s AI search comeback and the licensed-content model
07:14 – Medicare’s rate stance: $90B shock and why insurers will push back
10:10 – 872 drug price hikes and where pricing power ends
10:25 – Preservatives linked to cancer and diabetes risk: what the studies claim
11:46 – China’s biotech blitz and US strategic drift
13:59 – Europe rewires: EU–India deal, US–India move, and the sovereignty push
15:58 – Google cyber offensive and botnet disruption
17:07 – Germany EV credits, EU satellite comms, and the “decoupling” problem
18:45 – ECB: the WTO and China as the inflection point
20:06 – One good thing: Japan’s 603 km/h maglev
21:21 – Wrap
FOLLOW GOOD REVENUE
- YouTube: https://www.youtube.com/channel/UCHrhuWbpYnUwrR75H2Ip4yQ
- Spotify: https://open.spotify.com/show/44me6PABSQ0k0GfphM70au
- Apple Podcast: https://podcasts.apple.com/us/podcast/good-revenue/id1707461473
Hosted on Acast. See acast.com/privacy for more information.